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419* Criteria for diagnosis of CF in the French Registry
L. Lemonnier1, S. Ravilly1, A. Munck2, M. Roussey2. 1Vaincre la Mucoviscidose,
Paris, France; 2AFDPHE, Paris, France
CF postnatal diagnosis is not always straightforward and this directly inﬂuences
inclusion of patients in registries. Newborn screening programs allow very early
diagnosis, often at a presymptomatic stage, increasing the number of equivocal
diagnosis.
Aim: To evaluate diagnosis circumstances of patients enrolled in the French CF
Registry database according to the recent CFF consensus recommendations (Farrell
et al, 2008).
Methods: The French CF Registry has been collecting data since 1992. Diagnosis
data at inclusion are sweat test (ST), CFTR mutations and symptoms.
Results: In 2006, 4994 patients were enrolled in the registry, 4886 were included
in the analysis (exclusion of prenatal diagnosis). CF diagnosis was unquestionable
in 4126 (84%) patients [abnormal ST (60%) and/or 2 CF-causing mutations (64%),
clinical symptoms (72%)].
For the remaining 760 patients with 1 or 0 identiﬁed CF causing mutation, ST
was intermediate, normal, unclassiﬁed or missing. At the time of enrolment, 68%
had clinical symptoms suggestive of CF (table). Expanded genetic testing identiﬁed
mutations in 527 patients (1 mutation, n = 461, 2 mutations, n = 66) but classiﬁcation
of these patients remains uncertain.
Conclusion: According to the recent CFF consensus recommendations, 84% of the
French Registry’s patients met the criteria for CF. Further analysis, in collaboration
with the CF centres and the French Association of Neonatal Screening (AFDPHE),
is under way to take into account enlarged data (pancreatic status, sputum culture)
during follow-up monitoring to improve the patients’ classiﬁcation.
Symptoms ST
Intermediate Normal Unclassiﬁeda Missing data Total
Yes 21 28 149 342 540
No 25 21 58 116 220
Total 46 49 207 458 760
aDue to lack of technique reference.
420* Extensive carrier testing and CF birth prevalence: evidence for
a negative correlation
C. Castellani1, L. Picci2, A. Tamanini3, A. Capodaglio1, P. Girardi4, P. Rizzotti3,
B.M. Assael1. 1CF Centre, Ospedale Civile Maggiore, Verona, Italy; 2Department
of Pediatrics, University of Padua, Padua, Italy; 3Laboratorio Analisi, Ospedale
Civile Maggiore, Verona, Italy; 4Unit of Epidemiology and Medical Statistics,
University of Verona, Verona, Italy
Aim of the study was to evaluate if extensive CF carrier testing may be connected
with the progressive decrease of CF birth incidence recorded in North Eastern Italy.
From 1993 to 2007 an average 52,000 newborns per year underwent Neonatal
Screening (NS), and 198 newborns with CF were detected (1/3937). A time related
contraction in birth prevalence was conﬁrmed, with an average annual percent
decrease of 0.15 per 10,000 neonates (Poisson regression analysis p 0.003). In
the NS area two sections were identiﬁed: the Western Region (WR), where CF
carrier testing is not offered to couples from the general population, and the
Eastern Region (ER), where CF carrier testing is widely offered to couples from
the general population. In ER from 1995 to 2007 such testing practice has been
steadily expanding, with a total of 87,721 CF carrier tests performed, 3460 carriers
identiﬁed, and 238 carrier couples detected (data collection in progress). The
prevalence of CF decreased by time (p< 0.001) but the rate of decrease was more
enhanced in ER as suggested by the existence of a statistically signiﬁcant (p = 0.014)
interaction term between time and region in the Poisson regression model. The
overall negative trend in North Eastern Italy is due to a contraction of CF births
in its Eastern part. In ER a negative correlation was found between CF incidence
and the number of carrier tests (p 0.012). Prenatal diagnosis data collection is in
progress. These data support the hypothesis that carrier screening may modify the
incidence of CF.
421 Rectal prolapse in CF: a population study
R. Scott-Jupp2, H.E. Kay1, K. Giles1. 1South and West Cystic Fibrosis Database,
Bath, United Kingdom; 2Salisbury District Hospital, Salisbury, United Kingdom
Rectal Prolapse (RP) has long been recognised as a presenting feature of CF. Older
literature suggested that it may have been caused by malnutrition and chronic
diarrhoea. We investigated whether this relationship exists in a contemporary
CF population, and whether any other features of CF are associated with RP at
presentation.
The South and West CF Database currently registers all 1268 CF patients from
1995 to 2007 from a deﬁned geographical area of England. For 1040 patients, data
on presenting features and annual review ﬁndings have been contributed by their
clinician. These data precede the adoption of universal neonatal screening.
65 (6.3%) presented with RP. The prevalences of other presenting features in those
with RP were compared with the CF database population (n = 1040): steatorrhoea
28 (43%) vs. 273 (26%); failure to thrive 16 (25%) vs. 443 (43%); respiratory 12
(18%) vs. 441 (42%).
In 24 (37%) RP was the only presenting feature. All RP cases were pancreatic
insufﬁcient. For each RP case 2 age- and sex-matched controls whose CF presented
with other symptoms were selected. There were no signiﬁcant differences between
cases and controls for: height, weight, % expected FEV1 (assessed at ages 6+,
10+ and 15+ years), prevalence of Delta-F 508 homozygosity. Cases acquired
pseudomonas for the ﬁrst time at an older age than controls (medians 6.5 vs.
2.5 years, p = 0.021). 12 cases and 23 controls died (n.s.).
We conclude that:
1. RP may be a presenting feature of CF in the absence of any other symptoms
2. RP is not associated with excessively poor nutrition and growth either at
presentation or subsequently
3. RP is not apparently associated with more severe respiratory illness and may be
associated with delayed acquisition of pseudomonas.
Supported by: Bath Unit for Research in Paediatrics.
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Cystic ﬁbrosis (CF) is the most common severe inherited monogenic disease
in Caucasians. In addition of the most frequent deltaF508 mutation which is
responsible for the 50−65% of the cases, more than 1300 different rare mutations
are present in the CFTR gene.
The goal of this study was to determine whether a speciﬁc mutation with Slavic
origin, namely CFTRdele2,3 (21 kb) is present among Eastern Hungarian CF
patients.
For the mutation analysis, 43 patients with severe CF phenotype were selected and
tested for the presence of the CFTRdele2,3 (21 kb) mutation using deletion speciﬁc
primers. The deletion point was analyzed by DNA sequencing. The parents were
also tested in the affected families. 4 patients of the 43 carried the CFTRdele2,3
(21 kb) mutation, all in heterozygous form and all together with deltaF508. In every
analyzed families, the CFTRdele2,3 (21 kb) segregated trans with the deltaF508
mutation being all patients compound heterozygous for the two abovementioned
mutations.
The CFTRdele2,3 (21 kb) mutation with Slavic origin is present in the Hungarian
CF patients. Its combination with the deltaF508 is more frequent than any other
previously tested mutation. Based on our data, it is recommended to include the
CFTRdele2,3 (21 kb) mutation analysis in the Hungarian CF mutation testing panel.
